Galapagos NV
ISIN
BE0003818359
Ticker
GLPG
Sector
Sub-Industry
Country
Belgium
Year Founded
1999
ISIN
BE0003818359
Ticker
GLPG
Sector
Sub-Industry
Country
Belgium
Year Founded
1999
We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Worldwide
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 03.07.2024 | Huston Thad | Board | Buy | EUR 0.00 |
| 17.05.2024 | Stoffels IMC | Board | Buy | EUR 0.00 |
| 01.05.2024 | Stoffels IMC | Board | Other | EUR 1,428,334.05 |
| 01.05.2024 | Missotten Annelies | Board | Other | EUR 373,990.65 |
| 01.05.2024 | Cnossen Valeria | Board | Other | EUR 368,885.55 |
| 01.05.2024 | Huston Thad | Board | Other | EUR 354,439.80 |
| 30.04.2024 | GILEAD THERAPEUTICS A1 UNLIMITED COMPANY | Close relation | Other | EUR 0.00 |
| 21.12.2023 | Guenter Peter | Board | Buy | EUR 23,069.75 |
| 21.12.2023 | Baker Daniel George | Board | Buy | EUR 22,736.24 |
| 21.12.2023 | Schaffert Susanne Antonie | Board | Buy | EUR 12,896.14 |
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| Qube Research & Technologies Ltd. | 0.50% | 18.09.23 |
| Arrowstreet Capital, Limited Partnership | 0.51% | 27.04.23 |
| Total | 1.01% |
BE0003818359
549300QKJ78IY0IOV655
BEL20
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.